NLSP - Exclusive Option Agreement May Catch Some Shorts

2023-12-01 08:22:37 ET

DENVER, Colo., Dec 1, 2023 ( www.247marketnews.com )- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced, this morning, that it entered into an exclusive worldwide option agreement with Aexon Labs, under which NLS may acquire global development and commercialization rights to Aexon Labs’ Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin-1 and orexin-2 receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders such as Parkinson’s and Alzheimer’s disease.

NLS Pharmaceutics is trading at $0.4923, up $0.0724 (+17.24%), on 5.1M shares traded

Its 52-week range is $0.26 to $1.88. This hit its 52-week low mid-November, but it’s reversing that trend. It’s already more than doubled its …

The post Exclusive Option Agreement May Catch Some Shorts appeared first on 24/7 Market News .

For further details see: